

## E-References

- e1. Komaki H, Hayashi YK, Tsuburaya R, et al. Inflammatory changes in infantile-onset LMNA-associated myopathy. *Neuromuscul Disord* 2011;21:563–568.
- e2. Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. *Ann Neurol* 2012;72:9–17.
- e3. Peat RA, Smith JM, Compton AG, et al. Diagnosis and etiology of congenital muscular dystrophy. *Neurology* 2008;71:312–321.
- e4. Clement EM, Feng L, Mein R, et al. Relative frequency of congenital muscular dystrophy subtypes: analysis of the UK diagnostic service 2001–2008. *Neuromuscul Disord* 2012;22:522–527.
- e5. Brinas L, Richard P, Quijano-Roy S, et al. Early onset collagen VI myopathies: Genetic and clinical correlations. *Ann Neurol* 2010;68:511–520.
- e6. Lampe AK, Dunn DM, von Niederhausern AC, et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. *J Med Genet* 2005;42:108–120.
- e7. Okada M, Kawahara G, Noguchi S, et al. Primary collagen VI deficiency is the second most common congenital muscular dystrophy in Japan. *Neurology* 2007;69:1035–1042.
- e8. Baker NL, Morgelin M, Pace RA, et al. Molecular consequences of dominant Bethlem myopathy collagen VI mutations. *Ann Neurol* 2007;62:390–405.
- e9. Dhamne M, DiCarlo S, Adesina A, Lotze T. F2 Child Neurology/Developmental Neurobiology: Genetic Spectrum of Pediatric Collagen 6 Myopathies. *Neurology* 2012;78(Meeting Abstracts 1):P05.138.
- e10. Bovolenta M, Neri M, Martoni E, et al. Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies. *BMC Med Gen* 2010;11:44.
- e11. Foley AR, Hu Y, Zou Y, et al. Large genomic deletions: a novel cause of Ullrich congenital muscular dystrophy. *Ann Neurol* 2011;69:206–211.
- e12. Baker NL, Morgelin M, Peat R, et al. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. *Hum Mol Genet* 2005;14:279–293.
- e13. Giusti B, Lucarini L, Pietroni V, et al. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. *Ann Neurol* 2005;58:400–410.
- e14. Higuchi I, Shiraishi T, Hashiguchi T, et al. Frameshift mutation in the collagen VI gene causes Ullrich's disease. *Ann Neurol* 2001;50:261–265.
- e15. Ishikawa H, Sugie K, Murayama K, et al. Ullrich disease due to deficiency of collagen VI in the sarcolemma. *Neurology* 2004;62:620–623.
- e16. Pace RA, Peat RA, Baker NL, et al. Collagen VI glycine mutations: perturbed assembly and a spectrum of clinical severity. *Ann Neurol* 2008;64:294–303.
- e17. Gualandi F, Urciuolo A, Martoni E, et al. Autosomal recessive Bethlem myopathy. *Neurology* 2009;73:1883–1891.
- e18. Oliveira J, Santos R, Soares-Silva I, et al. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. *Clin Genet* 2008;74:502–512.

- e19. Pegoraro E, Marks H, Garcia CA, et al. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. *Neurology* 1998;51:101–110.
- e20. Pegoraro E, Mancias P, Swerdlow SH, et al. Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. *Ann Neurol* 1996;40:782–791.
- e21. Tezak Z, Prandini P, Boscaro M, et al. Clinical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (LAMA2) deficiency. *Hum Mutat* 2003;21:103–111.
- e22. Vainzof M, Richard P, Herrmann R, et al. Prenatal diagnosis in laminin alpha2 chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five international centers. *Neuromuscul Disord* 2005;15:588–594.
- e23. Siala O, Kammoun Feki F, Louhichi N, et al. Molecular prenatal diagnosis of muscular dystrophies in Tunisia and postnatal follow-up role. *Genet Test* 2008;12:581–586.
- e24. Mercuri E, Messina S, Bruno C, et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: a population study. *Neurology* 2009;72:1802–1809.
- e25. Messina S, Mora M, Pegoraro E, et al. POMT1 and POMT2 mutations in CMD patients: a multicentric Italian study. *Neuromuscul Disord* 2008;18:565–571.
- e26. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. *Hum Mol Genet* 2003;12:2853–2861.
- e27. Devisme L, Bouchet C, Gonzales M, et al. Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. *Brain* 2012;135:469–482.
- e28. Godfrey C, Clement E, Abbs S, Muntoni F. Exclusion of WWP1 mutations in a cohort of dystroglycanopathy patients. *Muscle Nerve* 2011;44:388–392.
- e29. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. *Nature* 1998;394:388–392.
- e30. Kondo-Iida E, Kobayashi K, Watanabe M, et al. Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). *Hum Mol Genet* 1999;8:2303–2309.
- e31. Yoshioka M, Higuchi Y, Fujii T, Aiba H, Toda T. Seizure-genotype relationship in Fukuyama-type congenital muscular dystrophy. *Brain Dev* 2008;30:59–67.
- e32. Hehr U, Uyanik G, Gross C, et al. Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease. *Neurogenetics* 2007;8:279–288.
- e33. Manzini MC, Gleason D, Chang BS, et al. Ethnically diverse causes of Walker-Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East. *Hum Mutat* 2008;29:E231–E241.
- e34. de Bernabe DB, van Bokhoven H, van Beusekom E, et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. *J Med Genet* 2003;40:845–848.
- e35. Currier SC, Lee CK, Chang BS, et al. Mutations in POMT1 are found in a minority of patients with Walker-Warburg syndrome. *Am J Med Genet A* 2005;133A:53–57.
- e36. Messina S, Bruno C, Moroni I, et al. Congenital muscular dystrophies with cognitive impairment. A population study. *Neurology* 2010;75:898–903.

- e37. Di Rosa G, Messina S, D'Amico A, et al. A new form of alpha-dystroglycanopathy associated with severe drug-resistant epilepsy and unusual EEG features. *Epileptic Disord* 11;13:259–262. [Published with video sequences.]
- e38. Pane M, Messina S, Vasco G, et al. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. *Neuromuscul Disord* 2012;22:685–689.
- e39. Nadeau A, Kinali M, Main M, et al. Natural history of Ullrich congenital muscular dystrophy. *Neurology* 2009;73:25–31.
- e40. Khan Y, Heckmatt JZ, Dubowitz V. Sleep studies and supportive ventilatory treatment in patients with congenital muscle disorders. *Arch Dis Child* 1996;74:195–200.
- e41. Cil E, Topaloglu H, Caglar M, Ozme S. Left ventricular structure and function by echocardiography in congenital muscular dystrophy. *Brain Dev* 1994;16:301–303.
- e42. Ceviz N, Alehan F, Alehan D, et al. Assessment of left ventricular systolic and diastolic functions in children with merosin-positive congenital muscular dystrophy. *Int J Cardiol* 2003;87:129–133; discussion 133–124.
- e43. Falsaperla R, Romeo G, Mattia C, Pavone P, Quattrochi S. Subclinical cardiological involvement in Sicilian patients with pure congenital muscular dystrophy. *Minerva Pediatr* 2005;57:275–279.
- e44. Philpot J, Bagnall A, King C, Dubowitz V, Muntoni F. Feeding problems in merosin deficient congenital muscular dystrophy. *Arch Dis Child* 1999;80:542–547.
- e45. Takaso M, Nakazawa T, Imura T, et al. Surgical correction of spinal deformity in patients with congenital muscular dystrophy. *J Orthop Sci* 2010;15:493–501.
- e46. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2009;73:1227–1233.
- e47. Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: coming into focus. *Curr Opin Genet Dev* 2011;21:278–285.
- e48. Ries NM, Hyde-Lay R, Caulfield T. Willingness to pay for genetic testing: a study of attitudes in a Canadian population. *Public Health Genomics* 2010;13:292–300.
- e49. Boyden SE, Mahoney LJ, Kawahara G, et al. Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores. *Neurogenetics* 2012;13:115–124.
- e50. Wang CH, Bönnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. *J Child Neurol* 2010;25:1559–1581.
- e51. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol* 2007;22:1027–1049.
- e52. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. *Am J Respir Crit Care Med* 2004;170:456–465.
- e53. Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. *Pediatrics* 2009;123 Suppl 4:S245–S249.
- e54. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

- and the Practice Committee of the Child Neurology Society. *Neurology* 2010;74:336–343.
- e55. Davies B, Sehring SA, Partridge JC, et al. Barriers to palliative care for children: perceptions of pediatric health care providers. *Pediatrics* 2008;121:282–288.
- e56. Khan N, Brown A, Venkataraman ST. Predictors of extubation success and failure in mechanically ventilated infants and children. *Crit Care Med* 1996;24:1568–1579.
- e57. Ramelli GP, Aloysius A, King C, Davis T, Muntoni F. Gastrostomy placement in paediatric patients with neuromuscular disorders: indications and outcome. *Dev Med Child Neurol* 2007;49:367–371.
- e58. Finsterer J, Ramaciotti C, Wang CH, et al. Cardiac findings in congenital muscular dystrophies. *Pediatrics* 2010;126:538–545.
- e59. Nakanishi T, Sakauchi M, Kaneda Y, et al. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. *Pediatrics* 2006;117:e1187–e1192.
- e60. Stubgen JP. Rigid spine syndrome: a noninvasive cardiac evaluation. *Pediatr Cardiol* 2008;29:45–49.
- e61. de Visser M, de Voogt WG, la Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. *Muscle Nerve* 1992;15:591–596.
- e62. Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. *Am Heart J* 1998;136:474–476.
- e63. van der Kooi AJ, de Voogt WG, Bertini E, et al. Cardiac and pulmonary investigations in Bethlem myopathy. *Arch Neurol* 2006;63:1617–1621.
- e64. Wahbi K, Meune C, Hamouda el H, et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. *Neuromuscul Disord* 2008;18:650–655.
- e65. Finsterer J, Stollberger C. The heart in human dystrophinopathies. *Cardiology* 2003;99:1–19.
- e66. Finsterer J, Stollberger C. Cardiac involvement in Becker muscular dystrophy. *Can J Cardiol* 2008;24:786–792.
- e67. Nigro G, Comi LI, Politano L, et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. *Muscle Nerve* 1995;18:283–291.
- e68. Hoogerwaard EM, de Voogt WG, Wilde AA, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. *J Neurol* 1997;244:657–663.
- e69. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. *Am J Cardiol* 2012;110:98–102.
- e70. Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. *Chest* 2007;132:1977–1986.
- e71. Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and perioperative medical management of children with spinal muscular atrophy. *Paediatr Anaesth* 2009;19:1054–1063.

- e72. Graham RJ, Wachendorf MT, Burns JP, Mancuso TJ. Successful and safe delivery of anesthesia and perioperative care for children with complex special health care needs. *J Clin Anesth* 2009;21:165–172.
- e73. Martyn JA, White DA, Gronert GA, Jaffe RS, Ward JM. Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers. *Anesthesiology* 1992;76:822–843.
- e74. Wick S, Muenster T, Schmidt J, Forst J, Schmitt HJ. Onset and duration of rocuronium-induced neuromuscular blockade in patients with Duchenne muscular dystrophy. *Anesthesiology* 2005;102:915–919.
- e75. Ihmsen H, Schmidt J, Schwilden H, Schmitt HJ, Muenster T. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy. *Anesthesiology* 2009;110:1016–1019.
- e76. Diefenbach C, Lynch J, Abel M, Buzello W. Vecuronium for muscle relaxation in patients with dystrophia myotonica. *Anesth Analg* 1993;76:872–874.
- e77. Individuals with Disabilities Education Improvement Act of 2004, Pub L No 108-446, 20 USC 1400.
- e78. Bönnemann CG, Rutkowski A, Mercuri E, Muntoni F. 173rd ENMC International Workshop: congenital muscular dystrophy outcome measures 5-7 March 2010, Naarden, The Netherlands. *Neuromuscul Disord* 2011;21:513–522.
- e79. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bönnemann CG, Chu ML. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. *Am J Hum Genet* 2003;73:355–369.
- e80. Demir E, Sabatelli P, Allamand V, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. *Am J Hum Genet* 2002;70:1446–1458.
- e81. Jobsis GJ, Keizers H, Vreijling JP, et al. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. *Nat Genet* 1996;14:113–115.
- e82. Pan TC, Zhang RZ, Pericak-Vance MA, et al. Missense mutation in a von Willebrand factor type A domain of the alpha 3(VI) collagen gene (COL6A3) in a family with Bethlem myopathy. *Hum Mol Genet* 1998;7:807–812.
- e83. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. *Dev Cell* 2001;1:717–724.
- e84. Beltran-Valero de Bernabe D, Voit T, Longman C, et al. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. *J Med Genet* 2004;41:e61.
- e85. Mercuri E, D'Amico A, Tessa A, et al. POMT2 mutation in a patient with 'MEB-like' phenotype. *Neuromuscul Disord* 2006;16:446–448.
- e86. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. *Am J Hum Genet* 2002;71:1033–1043.
- e87. van Reeuwijk J, Janssen M, van den Elzen C, et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. *J Med Genet* 2005;42:907–912.

- e88. Taniguchi K, Kobayashi K, Saito K, et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. *Hum Mol Genet* 2003;12:527–534.
- e89. Willer T, Lee H, Lommel M, et al. ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. *Nat Genet* 2012;44:575–580.
- e90. Roscioli T, Kamsteeg EJ, Buysse K, et al. Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of alpha-dystroglycan. *Nat Genet* 2012;44:581–585.
- e91. Cirak S, Foley AR, Herrmann R, et al. ISPD gene mutations are a common cause of congenital and limb-girdle muscular dystrophies. *Brain* 2013;136:269–281.
- e92. Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. *Nat Genet* 2001;29:17–18.
- e93. Shalaby S, Hayashi YK, Goto K, et al. Rigid spine syndrome caused by a novel mutation in four-and-a-half LIM domain 1 gene (FHL1). *Neuromuscul Disord* 2008;18:959–961.
- e94. Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. *Am J Hum Genet* 2002;71:739–749.
- e95. Quijano-Roy S, Mbieleu B, Bönnemann CG, et al. De novo LMNA mutations cause a new form of congenital muscular dystrophy. *Ann Neurol* 2008;64:177–186.